RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability

Ann O’Mara, PhD
Division Cancer Prevention
Symptom Management Research Implementation Team
1. Goals of the RFA
2. Important dates
3. Examples of
   - Eligible projects
   - Ineligible projects
4. Key aspects of projects
Goals of RFA

1. Support projects that explore analytic approaches of clinical trial data that have used both the Common Terminology Criteria for Adverse Events (CTCAE) and the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™).

2. Outcomes from these projects will allow better insights into patient tolerability of agents and regimens undergoing testing in cancer clinical trials.
Important Dates

- Application due date: **January 17, 2018**
- Late applications will not be accepted
- Scientific Merit Review: June-July 2018
- Advisory Council Review: August 2018
- Earliest Start Date: September 2018
Examples of:

**Eligible Submissions**
- Analyzing longitudinal data of CTCAE grades, PRO-CTCAE scores, other PRO scores, and dose modifications
- Employing pharmacokinetic data in conjunction with PRO-CTCAE scores and CTCAE grading
- Representing the data using different graphical techniques
- Multiple datasets, with at least one having both CTCAE grades and PRO-CTCAE scores

**Ineligible Submissions**
- At least one dataset lacking both CTCAE grades and PRO-CTCAE scores
- Projects proposing to prospectively collect CTCAE grades and PRO-CTCAE scores
- Data collected outside clinical trial setting
- Data collected in disease settings other than cancer
Key Aspects of Projects

- An operational definition of tolerability that relates to the patient- and clinician-reported data that will be used in the analyses.
- Address how minority health and/or health disparity populations or data will be integrated into the proposed studies.
- Have at least one clinical trial dataset with CTCAE and PRO-CTCAE data
- Must use existing data sources rather than collect new data.
- Describe the clinical trial(s) in which the data were collected.
- Describe the dataset, including sample size, demographics of the patient population, frequency of data collection, and types of data collected
- Investigators will share their analytic approaches and methods with members of the consortium and the Steering Committee.
Key Aspects (cont.)

- Each funded research team will be comprised of at least one of each of the following:
  - Biostatistician
  - Data scientist (combined expertise of biostatistician and data scientist is acceptable),
  - Clinical trialist
  - PRO measurement expert.
- Creation of a consortium of the funded research teams, academic investigators, industry sponsors, NCI and regulatory staff and patient advocates
- Establishment of a Steering Committee to:
  - Identify areas of opportunity that can best be exploited with a group effort of the awardees;
  - Encourage development of new methodologies and approaches for sharing among awardees;
  - Optimize information flow among the awardees and the NCI.
Everything You Need to Know about the RFA

Questions?

NCIpatient_tolerabilityRFA@mail.nih.gov